Literature DB >> 1981534

Taxol metabolism. Isolation and identification of three major metabolites of taxol in rat bile.

B Monsarrat1, E Mariel, S Cros, M Garès, D Guénard, F Guéritte-Voegelein, M Wright.   

Abstract

The elimination of nonradioactive taxol in bile and urine was investigated in the rat after administration via the caudal vein (10 mg/kg). As in humans, no metabolites of taxol were detected by HPLC in rat urine, and only 10% of the injected taxol was recovered in urine over a 24-hr period. In contrast, 11.5% and 29% of the injected taxol was recovered in rat bile as unchanged taxol and metabolites, respectively. Among the nine taxol metabolites detected by HPLC, the side chain at C13, which is required for pharmacological activity, had been removed in only one minor metabolite, baccatin III. The chemical structures of the two major hydroxylated metabolites were determined by mass spectrometry (fast atom bombardment and desorption chemical ionization) and 1H-NMR spectroscopy. One was a taxol derivative hydroxylated on the phenyl group at C3' of the side chain at C13, while the other corresponded to a taxol derivative hydroxylated in the m-position on the benzoate of the side chain at C2. Although these two major taxol metabolites were as active as taxol in preventing cold microtubule disassembly, they were, respectively, 9 and 39 times less cytotoxic as taxol on in vitro L1210 leukemia growth. These results show for the first time that there is a significant hepatic metabolism of taxol.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1981534

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  16 in total

1.  Fluorine-Containing Taxoid Anticancer Agents and Their Tumor-Targeted Drug Delivery.

Authors:  Joshua Seitz; Jacob G Vineberg; Edison S Zuniga; Iwao Ojima
Journal:  J Fluor Chem       Date:  2013-08-01       Impact factor: 2.050

2.  A Hyperresponsive HPA Axis May Confer Resilience Against Persistent Paclitaxel-Induced Mechanical Hypersensitivity.

Authors:  Sharon L Kozachik; Gayle G Page
Journal:  Biol Res Nurs       Date:  2015-10-27       Impact factor: 2.522

Review 3.  Interactions between antiretrovirals and antineoplastic drug therapy.

Authors:  Tony Antoniou; Alice L Tseng
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

4.  Strategic Incorporation of Fluorine into Taxoid Anticancer Agents for Medicinal Chemistry and Chemical Biology Studies.

Authors:  Iwao Ojima
Journal:  J Fluor Chem       Date:  2017-01-03       Impact factor: 2.050

5.  Steady-state plasma concentrations and effects of taxol for a 250 mg/m2 dose in combination with granulocyte-colony stimulating factor in patients with ovarian cancer.

Authors:  C A Jamis-Dow; R W Klecker; G Sarosy; E Reed; J M Collins
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

6.  Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice.

Authors:  J L Eiseman; N D Eddington; J Leslie; C MacAuley; D L Sentz; M Zuhowski; J M Kujawa; D Young; M J Egorin
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

7.  Metabolism of taxol by human and rat liver in vitro: a screen for drug interactions and interspecies differences.

Authors:  C A Jamis-Dow; R W Klecker; A G Katki; J M Collins
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

8.  Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy.

Authors:  Stefanie D Krens; Howard L McLeod; Daniel L Hertz
Journal:  Pharmacogenomics       Date:  2013-04       Impact factor: 2.533

Review 9.  Clinical pharmacokinetics of paclitaxel.

Authors:  D S Sonnichsen; M V Relling
Journal:  Clin Pharmacokinet       Date:  1994-10       Impact factor: 6.447

10.  Paclitaxel metabolism in rat and human liver microsomes is inhibited by phenolic antioxidants.

Authors:  Radka Václavíková; Stanislav Horský; Petr Simek; Ivan Gut
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-08-14       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.